Monday 9 November 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
2
Average plausibility
75%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01PoliticsGlobal

COP31 opens with pressure to turn climate pledges into action

Reports agree on the UN summit’s location and opening date, but its promise to turn commitments into action remains untested.

DW reports that COP31 is opening in Antalya, Turkey, with droughts, floods and extreme heat adding pressure on delegates. November 9 coverage from Reuters, AFP and RTÉ places the UN climate talks in Turkey and describes participation from nearly 200 countries. AFP reports that organizers are calling it the “implementation COP,” while Reuters highlights energy security and rising electricity demand as obstacles to climate goals.

What holds up

  • ✓Reuters, AFP’s report carried by RFI, and RTÉ agree that the talks open November 9 in Turkey; their coverage also places the gathering in Antalya. This supports DW’s central account, although the excerpts mostly describe the opening prospectively rather than document an opening ceremony.
  • ✓The push to deliver on existing promises is a stated summit priority: AFP reports the organizers’ “implementation COP” branding, and RTÉ describes pressure to deliver commitments, especially financial help for vulnerable countries.

What doesn't yet

  • ?DW links droughts, floods and extreme heat to pressure on delegates, but its excerpt provides no measurements or delegate testimony establishing that link. Other reports describe broader climate urgency without checking those specific hazards.
  • ?An action-focused label does not establish results. Reuters reports criticism that Turkey’s proposed electrification pledge does not require the extra electricity to come from low-carbon sources; AFP describes parallel action-agenda pledges as nonbinding.
  • ?France 24 and RFI carry matching passages from the AFP account, so they do not provide separate confirmation. The supplied snippets and excerpts are not full-article verification, and none supplies an official opening record.

Ask before you share

  • →Which summit commitments will include funding, deadlines and public progress checks rather than voluntary promises?
  • →What evidence connects the cited droughts, floods and heat to delegates’ priorities at this meeting?
  • →Will the proposed electrification pledge require cleaner power, and how will countries measure any resulting emissions cuts?

Sources & original reporting

  1. [1]DW · Published 8 Nov 2026 · dw.com
  2. [2]France 24 · Published 9 Nov 2026 · france24.com
  3. [3]Rfi · Published 9 Nov 2026 · rfi.fr
  4. [4]Reuters · Published 9 Nov 2026 · reuters.com
  5. [5]Rte · Published 9 Nov 2026 · rte.ie
02HealthGlobal

Baxdrostat report suggests blood pressure benefits may outlast treatment

Reports describe benefits lasting up to two years after treatment in a small, selected group, not proof that baxdrostat can permanently cure high blood pressure.

The Guardian reports that some patients’ blood pressure stayed lower for up to two years after they stopped taking baxdrostat. The i and Mirror describe a follow-up involving 14 patients who had already responded strongly during an initial trial and then continued treatment. The reports raise the possibility of a lasting effect on a hormonal cause of high blood pressure, but the supplied excerpts do not establish a permanent cure.

What holds up

  • ✓The Guardian, the i and Mirror describe lasting benefits after treatment. The i and Mirror agree that the follow-up involved 14 patients selected after substantial initial improvements, an important limit on how widely the results apply.
  • ✓Separate background evidence supports blood pressure lowering during treatment: a July trial abstract indexed by PubMed reports a 14 mm Hg greater reduction in average 24-hour systolic pressure with baxdrostat than placebo at 12 weeks. That does not establish benefits after stopping.

What doesn't yet

  • ?The i suggests baxdrostat could kill hormone-producing tumor cells and have permanent effects; the Guardian and Mirror also use cure language. The excerpts provide no direct evidence of cell destruction, and follow-up lasting up to two years cannot establish permanence.
  • ?The excerpts do not show how many patients reached two years of follow-up, whether there was a comparison group after stopping, or how other medications changed. Mirror reports that just under a quarter stopped all blood pressure treatment, so stopping baxdrostat should not be confused with stopping every medication.
  • ?Only a few outside newsrooms provide relevant coverage of the lasting-effect finding, and other accounts may be missing. UA News explicitly repeats the Guardian; multiple retellings of the same study are not separate clinical confirmation. These snippets are not full-article or study verification.

Ask before you share

  • →How many of the 14 patients maintained lower blood pressure for the full two years, and what other treatments were they taking?
  • →Did researchers compare these selected strong responders with similar patients who stopped treatment, and did they directly measure changes in hormone-producing cells?
  • →Which patients could benefit, and will a larger study confirm lasting effects and assess safety?

Sources & original reporting

  1. [1]The Guardian · Published 8 Nov 2026 · theguardian.com
  2. [2]Inews · Published 7 Nov 2026 · inews.co.uk
  3. [3]Mirror · Published 8 Nov 2026 · mirror.co.uk
  4. [4]Ua · Published 8 Nov 2026 · ua.news
  5. [5]Pubmed Ncbi Nlm Nih · Published 3 Jul 2026 · pubmed.ncbi.nlm.nih.gov